Short summary

Chemotherapy-induced peripheral neuropathy is an adverse side effect to commonly used chemotherapy. Newer research within the field have studied, neurofilament light chain as a biomarker for chemotherapy-induced peripheral neuropathy and have found promising results. We want to investigate if neurofilament light chain can be used as biomarker for bortezomib-induced peripheral neuropathy.

Rationale

The aim of the project is to investigate whether a blood sample can be used to predict which patients have increased risk of developing peripheral neuropathy when treated with bortezomib.

Description of the cohort

Paticipants are patients with multiple myeloma included at Odense University Hospital and Aarhus University Hospital. They must be 18 years of age or above, and candidates for treatment with bortezomib. They can not be candidates for staem cell transplantation.

Data and biological material

Categoric data is collected: demografic, type of diagnose, data from the patient journal and questionnaire data. Blood samples are collected for measurement of plasma level of neurofilament light chain.

Collaborating researchers and departments

Department of Blood Diseases, Aarhus University Hospital

• Mette Kathrine Nygaard

Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark

• Tore Bjerregaard Stage

Department of Haematology X, Odense University Hospital

• Thomas Lund
• Ida Bruun Kristensen

Department of Immunology and Biochemistry, Lillebaelt Hospital, Vejle

• Jonna Skov Madsen